Individuals who are able to maintain or decrease their blood pressure (BP) to normal levels during middle age have the lowest lifetime risk for cardiovascular disease. In contrast, individuals who experience an increase in BP have higher lifetime risks, according to a study published in Circulation.
Individuals who are able to maintain or decrease their blood pressure (BP) to normal levels during middle age have the lowest lifetime risk for cardiovascular disease (CVD). In contrast, individuals who experience an increase in BP have higher lifetime risks (LTRs), according to a study published in Circulation.
“Avoiding hypertension before middle age and delaying the onset of the development of hypertension both appear to have a significant impact on an individual’s remaining lifetime risk for CVD,” wrote Norrina Allen, PhD, of the Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, and colleagues.
The researchers examined the impact of blood-pressure changes over time during middle age on lifetime risk for cardiovascular disease by using data from the Cardiovascular Lifetime Risk Pooling Project. They followed 61,585 white and black men and women from an index age of 55 for 695,394 person-years. The participants were followed until the occurrence of a first CVD event, death, or until they reached age 95 years.
The data demonstrated that the remaining lifetime risk for CVD, starting at age 55 years, was 52.5% (95% CI, 51.3–53.7) for men and 39.9% (38.7–41.0) for women. For coronary heart disease (CHD), lifetime risk was 30.9% (95% Cl, 29.8–31.9%) for men and 17.5% (16.6–18.3%) for women. And, for stroke, remaining lifetime risk was 11.2% (95% Cl, 10.3–12.1%) for men and 14.7% (13.6–15.8%) for women. Black participants reached a higher LTR at a younger age than white participants at almost all blood-pressure levels, the investigators noted.
The authors noted that women who developed hypertension by age 41 years had a higher lifetime risk for CVD and CHD compared to those who had developed hypertension late by age 55 years. A similar pattern was seen among men when examining the remaining lifetime risk of stroke, suggesting there may be a dose-response effect for length of time at higher blood pressures.
“Taking blood pressure changes into account can provide more accurate estimates for lifetime risk for cardiovascular disease and represent a step forward in developing individualized risk prediction strategies,” the authors wrote.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.